Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Ocular Therapeutix Enrolls First Patient in Phase 3 Wet AMD Study
Ocular Therapeutix announced that the first patients have been enrolled in its Phase 3 SOL-R clinical trial. This study aims to assess the repeat dosing of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for treating wet age-related macular degeneration…
Nicox Concludes U.S. Recruitment for Phase 3 NCX 470 Trial
Nicox announced the recruitment and randomization of the final patient in the United States for its Denali Phase 3 trial of NCX 470. This milestone marks a significant step in evaluating the safety and efficacy of NCX 470 for patients…
Eyenovia and Senju Collaborate on Novel Dry Eye Treatment
Eyenovia, a leading ophthalmic company, announced a collaboration agreement with Senju Pharmaceutical to develop SJP-0035, a corneal epithelial wound healing candidate, using Eyenovia’s Optejet® dispensing technology for chronic dry eye disease treatment. Strategic Collaboration for Innovative Treatment Under the agreement,…
Trial Results for Susvimo Show Sustained Efficacy in DME and DR
Genentech and Roche released compelling 2-year data from the phase 3 Pagoda and Pavilion studies evaluating Susvimo (ranibizumab injection) 100 mg/mL, marking a significant development in the treatment landscape for diabetic macular edema (DME) and diabetic retinopathy (DR). Reintroduction of…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…
FDA Clears Enhanced SPECTRALIS® OCTA Module by Heidelberg
Heidelberg Engineering announced the FDA clearance of its upgraded SPECTRALIS® OCTA Module featuring SHIFT technology. This advancement promises to significantly reduce acquisition time by 50%, marking a pivotal development in clinical efficiency and diagnostic precision within ophthalmology. Enhancing Clinical Utility…
Sydnexis Appoints Perry J. Sternberg as CEO
Sydnexis, Inc., a pioneering biopharmaceutical company dedicated to addressing pediatric myopia progression, has appointed Perry J. Sternberg as its Chief Executive Officer and as a member of its Board of Directors. Sternberg, a seasoned pharmaceutical and biotech executive with over…
Merck Completes Acquisition of EyeBio
Merck, known as MSD outside of the United States and Canada, announced the successful completion of its acquisition of Eyebiotech Limited (EyeBio), marking EyeBio as a fully owned subsidiary of Merck. “The EyeBio acquisition further diversifies our late-stage pipeline with…